Shots: Janssen to get exclusive WW license rights to develop & commercialize certain clinical candidates in MeiraGTx’s inherited retinal disease pipeline. Janssen also has an option to license the portfolio […]readmore
Tags : MeiraGTx
Shots: Vector’s acquisition is an all-stock transaction including its novel P-II drug candidate AAV-GAD evaluated for Parkinson’s Disease The acquisition focuses on developing candidate AAV-GAD and providing novel treatments for […]readmore